deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT03930732

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation (BOREAS)

A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation

Sponsor: Regeneron Pharmaceuticals

Conditions Chronic Obstructive Pulmonary Disease
Interventions Dupilumab SAR231893 Inhaled Corticosteroid Inhaled Long-Acting Beta Agonist Inhaled Long-Acting Muscarinic Antagonist Placebo
Updated 34 times since 2019 Last updated: Jan 30, 2024 Started: Apr 15, 2019 Primary completion: Feb 8, 2023 Completion: May 2, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Chronic Obstructive Pulmonary Disease and is currently completed. Regeneron Pharmaceuticals leads this study, which shows 34 recorded versions since 2019 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~May 2019 – ~Aug 2019 · 3 months · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Nov 2021 · 2 months · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Feb 2022 · 2 months · monthly snapshot~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~Jun 2022 · 3 months · monthly snapshot~Jun 2022 – ~Jun 2023 · 12 months · monthly snapshot~Jun 2023 – ~Mar 2024 · 9 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 8 months · monthly snapshot

Change History

34 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Mar 2024 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2023 — Mar 2024 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

▶ Show 29 earlier versions

  1. Jun 2022 — Jun 2023 [monthly]

    Active Not Recruiting PHASE3

  2. Mar 2022 — Jun 2022 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  3. Feb 2022 — Mar 2022 [monthly]

    Recruiting PHASE3

  4. Dec 2021 — Feb 2022 [monthly]

    Recruiting PHASE3

  5. Nov 2021 — Dec 2021 [monthly]

    Recruiting PHASE3

  6. Sep 2021 — Nov 2021 [monthly]

    Recruiting PHASE3

  7. May 2021 — Sep 2021 [monthly]

    Recruiting PHASE3

  8. Apr 2021 — May 2021 [monthly]

    Recruiting PHASE3

  9. Mar 2021 — Apr 2021 [monthly]

    Recruiting PHASE3

  10. Feb 2021 — Mar 2021 [monthly]

    Recruiting PHASE3

  11. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE3

  12. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  13. Nov 2020 — Dec 2020 [monthly]

    Recruiting PHASE3

  14. Oct 2020 — Nov 2020 [monthly]

    Recruiting PHASE3

  15. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE3

  16. Aug 2020 — Sep 2020 [monthly]

    Recruiting PHASE3

  17. Jul 2020 — Aug 2020 [monthly]

    Recruiting PHASE3

  18. Jun 2020 — Jul 2020 [monthly]

    Recruiting PHASE3

  19. May 2020 — Jun 2020 [monthly]

    Recruiting PHASE3

  20. Apr 2020 — May 2020 [monthly]

    Recruiting PHASE3

  21. Mar 2020 — Apr 2020 [monthly]

    Recruiting PHASE3

  22. Feb 2020 — Mar 2020 [monthly]

    Recruiting PHASE3

  23. Jan 2020 — Feb 2020 [monthly]

    Recruiting PHASE3

  24. Dec 2019 — Jan 2020 [monthly]

    Recruiting PHASE3

  25. Nov 2019 — Dec 2019 [monthly]

    Recruiting PHASE3

  26. Oct 2019 — Nov 2019 [monthly]

    Recruiting PHASE3

  27. Sep 2019 — Oct 2019 [monthly]

    Recruiting PHASE3

  28. Aug 2019 — Sep 2019 [monthly]

    Recruiting PHASE3

  29. May 2019 — Aug 2019 [monthly]

    Recruiting PHASE3

    First recorded

Apr 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Regeneron Pharmaceuticals
  • Sanofi
Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalborg, Denmark , Andalusia, United States , Ankara, Turkey (Türkiye) , Ann Arbor, United States , Ashkelon, Israel , Balassagyarmat, Hungary , Baltimore, United States , Banská Bystrica, Slovakia , Baotou, China , Barcelona, Spain and 218 more locations